Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours

Por Hoh, C K, Burris, H A, Bendell, J C, Tarazi, J, Rosbrook, B, Kim, S, Infante, J R, Reid, T R
Publicado em 2014

A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma

Por Rini, B., Redman, B., Garcia, J. A., Burris, H. A., Li, S., Fandi, A., Beck, R., Jungnelius, U., Infante, J. R.
Publicado no Ann Oncol (2014)

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

Por Younes, A, Vose, J M, Zelenetz, A D, Smith, M R, Burris, H A, Ansell, S M, Klein, J, Halpern, W, Miceli, R, Kumm, E, Fox, N L, Czuczman, M S
Publicado em 2010

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Por Rugo, H. S., Pritchard, K. I., Gnant, M., Noguchi, S., Piccart, M., Hortobagyi, G., Baselga, J., Perez, A., Geberth, M., Csoszi, T., Chouinard, E., Srimuninnimit, V., Puttawibul, P., Eakle, J., Feng, W., Bauly, H., El-Hashimy, M., Taran, T., Burris, H. A.
Publicado em 2014